BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 9426721)

  • 1. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA; Gormley GJ; Stoner E; Oesterling JE
    J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Brawer MK; Dixon CM; Gormley G; Haakenson C; Machi M; Narayan P; Padley RJ
    N Engl J Med; 1996 Aug; 335(8):533-9. PubMed ID: 8684407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
    Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].
    Morote J; Lorente JA; Raventós CX; López MA; Encabo G; De Torres I; López M; De Torres JA
    Actas Urol Esp; 1998; 22(10):835-9. PubMed ID: 9949572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
    Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
    Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study.
    Albertsen PC; Pellissier JM; Lowe FC; Girman CJ; Roehrborn CG
    Clin Ther; 1999 Jun; 21(6):1006-24. PubMed ID: 10440624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens].
    Zhang YG; Wang JY; Liu M; Wan B; Wei D; Deng SM; Xu J; Wu JY; Chu X; Zeng P
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1690-2. PubMed ID: 19024540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
    Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
    J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of men on finasteride.
    Gormley GJ
    Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
    Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
    Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
    J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
    Egawa S; Soh S; Ohori M; Uchida T; Gohji K; Fujii A; Kuwao S; Koshiba K
    Cancer; 1997 Jan; 79(1):90-8. PubMed ID: 8988731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.